Successful use of oral prostaglandin E1 derivative for maintaining ductus-dependent systemic circulation in a neonate with trisomy 18

Miyake, Akiko; Okada, Seigo; Ishikawa, Yuichi

doi:10.1017/s1047951119001902

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that the use of PGE1 analogs with oral bioavailability may overcome this practical problem. For instance, an oral PGE1 has been used instead of lipo‐PGE1 to maintain duct‐dependent systemic circulation in a neonate with trisomy‐18 38 . However, further research is required to explore whether an oral PGE1 analog may have effects similar to lipo‐PGE1 on patients undergoing PD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Wang

Tang

Xie

et al. 2021

Seminars in Dialysis

View full text Add to dashboard Cite

Social and healthcare improvements have prolonged individuals' lifespan worldwide, while they have resulted in an increased number of patients with end-stage renal disease (ESRD). 1 Peritoneal dialysis (PD) is extensively applied in the treatment of ESRD, with comparable outcomes to hemodialysis, including preservation of residual renal function, 2 being cost-effective, and higher quality of life. 3 In recent years, PD utilization has greatly attracted clinicians' attention in China, and over 250,000 patients have received PD according to the statistics reported in 2012. 4 However, peritoneal transport function gradually diminishes with the extended use of PD, and can eventually lead to ultrafiltration failure. [5][6][7] The dialysate/plasma creatinine ratio (D/Pcr) and the mass transfer area coefficient (MTAC) for urea (MTAC-urea) and creatinine (MTAC-creatinine) are commonly used indicators to assess peritoneal transport of small molecular solutes. 8 A specific correlation was reported between D/Pcr and MTAC-creatinine, and a change in MTAC can influence the effective peritoneal surface area. 9 In addition to the transport of creatinine and other small molecular

show abstract

Section: Discussionmentioning

confidence: 99%

“…with trisomy-18. 38 However, further research is required to explore whether an oral PGE1 analog may have effects similar to lipo-PGE1 on patients undergoing PD.…”

Section: Ta B L Ementioning

confidence: 99%

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Wang

Tang

Xie

et al. 2021

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

Liveborn children with trisomy 18: A scoping review

Schlosser,

MacPherson,

Castro-Codesal

et al. 2024

Journal of Neonatal-Perinatal Medicine

View full text Add to dashboard Cite

Background There have been an increasing number of publications related to trisomy 18 associated with a shift in the philosophy of care. The objective of this review is to understand the scope of contemporary literature informing the care of children born alive with trisomy 18. Methods Included was peer-reviewed, primary literature in MEDLINE, Embase, CINAHL, Scopus, Web of Science, and Cochrane Library from 2012 to 2023 reporting outcomes of children born alive with trisomy 18. Data extraction involved descriptive statistics of the types of studies, and an inductive thematic analysis of the questions addressed by the studies. Results Of 4628 records identified, 229 met inclusion criteria. Key themes were organized around the domains: What is trisomy 18? What are the chances of survival with trisomy 18? What can be done to improve the chances of survival with trisomy 18? How do children with trisomy 18 die? Do surgical interventions provide a benefit? Are there non-surgical options? What knowledge is informing medical management? How is life described for children with trisomy 18? What are children with trisomy 18 like as babies and as they get older? What is life like for families caring for children with trisomy 18? Conclusions A sizeable number of publications grouped trisomy 18 with other syndromes. Relatively few showed the longitudinal evolution of medical issues associated with trisomy 18, nor did they unfold the clinical heterogeneity of this population. This review shows the limited knowledge base guiding decision-making and care for children born alive with trisomy 18.

show abstract

Successful use of oral prostaglandin E1 derivative for maintaining ductus-dependent systemic circulation in a neonate with trisomy 18

Cited by 2 publications

References 10 publications

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Liveborn children with trisomy 18: A scoping review

Contact Info

Product

Resources

About